Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$45.7M Buy
1,898,971
+457,700
+32% +$12M 0.22% 89
2026
Q1
$40.5M Buy
1,441,271
+519,500
+56% +$13.8M 0.22% 91
2025
Q4
$23M Sell
921,771
-92,200
-9% -$2.33M 0.19% 109
2025
Q3
$25.8M Buy
1,013,971
+12,700
+1% +$313K 0.22% 93
2025
Q2
$24.3M Buy
1,001,271
+207,000
+26% +$4.83M 0.22% 98
2025
Q1
$20.1M Sell
794,271
-549,500
-41% -$14.4M 0.24% 90
2024
Q4
$35.6M Sell
1,343,771
-16,000
-1% -$434K 0.36% 45
2024
Q3
$39.4M Buy
+1,359,771
New +$39.7M 0.4% 44
2024
Q1
$44.3M Buy
1,595,571
+29,700
+2% +$824K 0.49% 37
2023
Q4
$45.1M Sell
1,565,871
-101,743
-6% -$3.08M 0.56% 31
2023
Q3
$55.3M Sell
1,667,614
-33,900
-2% -$1.2M 0.73% 24
2023
Q2
$62.4M Buy
1,701,514
+29,500
+2% +$1.15M 0.77% 25
2023
Q1
$68.2M Sell
1,672,014
-24,300
-1% -$1.05M 0.92% 21
2022
Q4
$86.9M Sell
1,696,314
-107,664
-6% -$5.16M 1.24% 10
2022
Q3
$94.6M Hold
1,803,978
1.19% 10
2022
Q2
$94.6M Buy
1,803,978
+392,200
+28% +$20M 1.19% 10
2022
Q1
$73.1M Sell
1,411,778
-83,699
-6% -$4.34M 0.72% 20
2021
Q4
$88.3M Sell
1,495,477
-92,934
-6% -$4.6M 0.78% 18
2021
Q3
$68.3M Sell
1,588,411
-23,200
-1% -$1.03M 0.63% 25
2021
Q2
$63.1M Sell
1,611,611
-85,900
-5% -$3.34M 0.58% 31
2021
Q1
$61.5M Buy
1,697,511
+28,200
+2% +$1M 0.56% 30
2020
Q4
$61.4M Sell
1,669,311
-107,639
-6% -$3.95M 0.58% 29
2020
Q3
$61.9M Buy
1,776,950
+62,291
+4% +$2.18M 0.67% 29
2020
Q2
$53.2M Buy
1,714,659
+86,217
+5% +$2.93M 0.67% 29
2020
Q1
$50.4M Sell
1,628,442
-71,461
-4% -$2.43M 0.81% 19
2019
Q4
$63.2M Sell
1,699,903
-44,162
-3% -$1.57M 0.78% 25
2019
Q3
$59.5M Sell
1,744,065
-18,713
-1% -$680K 0.77% 27
2019
Q2
$72.5M Sell
1,762,778
-137,126
-7% -$5.45M 0.93% 17
2019
Q1
$76.6M Buy
1,899,904
+379,642
+25% +$15.2M 0.96% 13
2018
Q4
$63M Sell
1,520,262
-113,094
-7% -$4.69M 1.09% 11
2018
Q3
$68.3M Sell
1,633,356
-108,401
-6% -$4.17M 1.01% 12
2018
Q2
$60M Sell
1,741,757
-52,246
-3% -$1.79M 0.91% 18
2018
Q1
$60.4M Buy
1,794,003
+17,084
+1% +$587K 0.92% 17
2017
Q4
$61.1M Buy
1,776,919
+272,862
+18% +$9.3M 0.93% 18
2017
Q3
$50.9M Buy
1,504,057
+51,381
+4% +$1.65M 0.97% 15
2017
Q2
$46.3M Buy
1,452,676
+167,857
+13% +$5.29M 0.93% 16
2017
Q1
$41.7M Sell
1,284,819
-82,241
-6% -$2.59M 1% 15
2016
Q4
$42.1M Sell
1,367,060
-139,549
-9% -$4.26M 0.99% 17
2016
Q3
$48.4M Buy
1,506,609
+8,264
+0.6% +$276K 1.06% 15
2016
Q2
$50.1M Buy
1,498,345
+18,215
+1% +$581K 1.16% 14
2016
Q1
$41.6M Buy
1,480,130
+189,012
+15% +$5.4M 0.96% 16
2015
Q4
$39.5M Buy
1,291,118
+6,704
+0.5% +$211K 1.04% 14
2015
Q3
$38.3M Sell
1,284,414
-81,707
-6% -$2.62M 1.07% 11
2015
Q2
$43.5M Sell
1,366,121
-137,014
-9% -$4.47M 1.05% 10
2015
Q1
$49.6M Sell
1,503,135
-89,441
-6% -$2.84M 1.14% 9
2014
Q4
$47.1M Sell
1,592,576
-119,363
-7% -$3.42M 1.02% 11
2014
Q3
$48M Sell
1,711,939
-141,560
-8% -$3.97M 1.03% 12
2014
Q2
$52.2M Sell
1,853,499
-130,864
-7% -$3.73M 1.04% 12
2014
Q1
$60.5M Buy
1,984,363
+29,009
+1% +$865K 1.2% 11
2013
Q4
$56.8M Sell
1,955,354
-88,253
-4% -$2.57M 1.19% 11
2013
Q3
$55.7M Sell
2,043,607
-177,909
-8% -$4.84M 1.2% 12
2013
Q2
$59M Buy
+2,221,516
New +$61.4M 1.23% 13

Other funds holding PFE

Fjarde Ap-fonden's PFE Position: Q2 2026 in Review

Fjarde Ap-fonden increased its Pfizer (PFE) stake by 32% in Q2 2026, buying an estimated $12M and bringing the position to 1,898,971 shares worth $45.7M. The position accounts for 0.22% of the portfolio, ranked #89.

Fjarde Ap-fonden first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $94.6M in Q3 2022. 1,179 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Fjarde Ap-fonden held 1,898,971 shares of Pfizer worth $45.7M as of Q2 2026.
  • Fjarde Ap-fonden bought 457,700 Pfizer shares in Q2 2026, an estimated $12M.
  • Pfizer made up 0.22% of Fjarde Ap-fonden's portfolio in Q2 2026, its #89 holding.
  • Fjarde Ap-fonden first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
  • Fjarde Ap-fonden's Pfizer position peaked at $94.6M in Q3 2022.
  • 1,179 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Fjarde Ap-fonden's 13F filing for Q2 2026, filed 29 Jul 2026.